Calliditas Therapeutics Stock Alpha and Beta Analysis
| CALT Stock | USD 20.56 0.08 0.39% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Calliditas Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Calliditas Therapeutics over a specified time horizon. Remember, high Calliditas Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Calliditas Therapeutics' market risk premium analysis include:
Beta 0.84 | Alpha (0.03) | Risk 3.47 | Sharpe Ratio (0) | Expected Return (0.01) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Calliditas |
Calliditas Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Calliditas Therapeutics market risk premium is the additional return an investor will receive from holding Calliditas Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Calliditas Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Calliditas Therapeutics' performance over market.| α | -0.03 | β | 0.84 |
Calliditas Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Calliditas Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Calliditas Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Calliditas Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Calliditas Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Calliditas Therapeutics shares will generate the highest return on investment. By understating and applying Calliditas Therapeutics stock market price indicators, traders can identify Calliditas Therapeutics position entry and exit signals to maximize returns.
Calliditas Therapeutics Return and Market Media
The median price of Calliditas Therapeutics for the period between Thu, Feb 8, 2024 and Wed, May 8, 2024 is 21.1 with a coefficient of variation of 6.27. The daily time series for the period is distributed with a sample standard deviation of 1.3, arithmetic mean of 20.79, and mean deviation of 1.03. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO | 03/06/2024 |
2 | Calliditas Therapeutics AB Shares Gap Down to 22.30 - MarketBeat | 03/18/2024 |
3 | Calliditas Therapeutics AB Stock Price Down 3.8 percent - MarketBeat | 03/26/2024 |
4 | Calliditas Therapeutics AB Shares Gap Up to 21.25 - MarketBeat | 04/04/2024 |
5 | Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment | 04/08/2024 |
6 | Calliditas Therapeutics AB About To Shift From Loss To Profit - Simply Wall St | 04/15/2024 |
7 | Calliditas reports positive Nefecon trial results for IgAN | 04/18/2024 |
8 | Calliditas Announces Positive NefIgArd Open Label Extension Results | 04/24/2024 |
9 | Calliditas releases phase 2 results on head and neck cancer asset setanaxib | 05/06/2024 |
About Calliditas Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Calliditas or other stocks. Alpha measures the amount that position in Calliditas Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2023 | 2024 (projected) | Payables Turnover | 0.0948 | 0.77 | 0.8 | Days Of Inventory On Hand | 87.57 | 96.76 | 73.74 |
Calliditas Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Calliditas Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Calliditas Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Calliditas Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Calliditas Therapeutics. Please utilize our Beneish M Score to check the likelihood of Calliditas Therapeutics' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Calliditas Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Calliditas Therapeutics Backtesting, Calliditas Therapeutics Valuation, Calliditas Therapeutics Correlation, Calliditas Therapeutics Hype Analysis, Calliditas Therapeutics Volatility, Calliditas Therapeutics History and analyze Calliditas Therapeutics Performance. For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Calliditas Stock analysis
When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Calliditas Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.